Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)

Next Previous
X
Search
Trial Profile

An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Crohn's disease; Non-alcoholic steatohepatitis; Portal hypertension; Primary bile acid malabsorption; Primary biliary cirrhosis
  • Focus Pharmacokinetics
  • Sponsors Intercept Pharmaceuticals

    • Most Recent Events

    • 18 Mar 2017 Results evaluating evidences from NCT01904539, NCT01473524, NCT00550862, NCT00570765 trials to recommend appropriate dosing in treatment of primary biliary cholagitis, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 31 Oct 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top